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Abstract
In clinical trials, a covariate-adjusted response-adaptive (CARA) design allows
a subject newly entering a trial a better chance of being allocated to a superior
treatment regimen based on cumulative information from previous subjects, and
adjusts the allocation according to individual covariate information. Since this
design allocates subjects sequentially, it is natural to apply a sequential method for
estimating the treatment effect in order to make the data analysis more efficient.
In this paper, we study the sequential estimation of treatment effect for a general
CARA design. A stopping criterion is proposed such that the estimates satisfy a
prescribed precision when the sampling is stopped. The properties of estimates
and stopping time are obtained under the proposed stopping rule. In addition, we
show that the asymptotic properties of the allocation function, under the proposed
stopping rule, are the same as those obtained in the non-sequential/fixed sample
size counterpart. We then illustrate the performance of the proposed procedure with
some simulation results using logistic models. The properties, such as the coverage
probability of treatment effect, correct allocation proportion and average sample
size, for diverse combinations of initial sample sizes and tuning parameters in the
utility function are discussed.
Key words: Covariate-adjustment, logistic regression, response-adaptive design, se-
quential estimation, stopping time, targeted drug, utility function
1. Introduction
From an ethical viewpoint, it is desirable to minimize the number of subjects allocated to
inferior treatments in the course of a clinical trial without jeopardizing the generation of
useful and meaningful statistical inferences. The response adaptive (RA) design in clinical
trials (Zelen and Wei 1995 and Hu and Rosenberger 2006) is dedicated to this purpose.
The advantage of an RA design is that the information collected from subjects previously
entering the trial can be used to adjust the allocation probability so that a newly entering
subject can have a better chance of being allocated to a superior treatment. Because
of the sequential characteristic in this process, sequential statistical methods should be
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used in order to efficiently analyze these kinds of data sets. Since data collected in this
manner are no longer independent, sequential methods that rely on assumption of inde-
pendent observations are not valid. Moreover, due to innovation in genomic technologies
and the nature of developing targeted drugs (Simon and Maitournam 2005), it is natu-
ral to incorporate the information available on individual covariates that have a strong
influence on responses to a model, since they may be associated with the efficacy of treat-
ments. Hence, the existence of an interaction between treatment and covariate becomes
a reasonable presumption as far as, for example, a targeted drug is concerned.
A situation where there is an interaction between covariates and treatments is illus-
trated in Figure 1. In this figure, a logistic model is used to describe the relation between
responses to treatments and covariates, where the covariates are generated from two nor-
mal distributions with a mean-shift denoting two sub-populations. Traditionally, we use
an RA design by assuming there is no treatment-covariate interaction effect; that is, the
slopes of treatments effects are assumed to be equal. However, when a treatment-covariate
interaction exists, as in Figure 1, this assumption is not valid, and the lines A and B in
this Figure will not be parallel. This implies that a method that uses RA design will
make incorrect treatment allocation, when such a non-ignorable interaction exists. In this
situation, it is reasonable to assume that a CARA design should perform better than an
RA design in terms of correct allocation proportions. However, up until now, little work
has been done on CARA designs. Since Figure 1 is for illustration purposes, it depicts an
extreme example of two treatments with opposite slopes. However, as long as the slopes
of the treatment effects are not equal, the two treatments make a lot of difference for sub-
jects with covariates located far from the intersection of the lines of the treatment effects.
Thus, as long as a targeted drug or other adaptive treatment strategy is being used, this
situation should not be ignored. In addition to the ethical considerations, this is a further
good reason for considering a CARA design. Further discussion about the properties
of RA and CARA designs can be found in, Bandyopadhyay, Biswas, and Bhattacharya
(2007), Bandyopadhyay and De (2009), Hu and Rosenberger (2006) and so on.
Although the sequential characteristics of RA and CARA designs are clear, and the
sequential sampling method, which allows the sample size to be determined based on
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the observed information, is known to be an adequate choice for making efficient and
valid statistical inference, most discussions in the literature to date have been limited to
the asymptotic properties of different designs. Even when the idea of a stopping rule
has been adopted, there has still been very little discussion of estimation under those
stopping criteria. Zhang and Hu (2009), and Bandyopadhyay and De (2009) are two
typical examples. In these two studies, only large scale simulation studies were conducted
to compare the properties of their designs and to provide information regarding suitable
sample sizes for their designs. In another example, Moler, Plo, and Miguel (2006) treated
the allocation ruled by an urn model as a Robbins-Monro scheme, but the property of the
stopping rule was still ignored. In addition, Thall and Wathen (2005) compared the CARA
design to the balanced randomization design, however, the same stopping rule based on
the balanced randomized design was applied to both designs, which is inappropriate as
indicated in their paper.
As mentioned above and also in Hu and Rosenberger (2006), the sequential method is
a natural choice for a CARA design based clinical trial; however, it is rare to find liter-
ature regarding the application of stopping rules for the sequential estimation procedure
based on CARA designs, and the effective sample size for a clinical trial with adaptive
design. The difficulties are mostly due to the adaptive nature of CARA designs, which
make the classical approach, based on the assumption of independent observation, less
useful. Besides the adaptive design, the adjustment of the allocation probability based
on subject’s covariate information makes the procedure even more complicated. Hence,
the asymptotic properties of estimates under randomly stopped CARA experiments, de-
rived in our paper, are not trivial and cannot follow from their non-random sample size
counterpart.
In this paper, a sequential procedure is proposed for estimating treatment effect under
a general CARA design. Our goal is to estimate the treatment effects, with the minimum
sample size, such that the estimates satisfy a prescribed precision, and subjects can be
allocated to the superior treatment without interfering with the the quality and efficiency
of estimation of treatment effects. The asymptotic properties of sequential estimates are
obtained under this general CARA design. In addition, we also show that the allocation
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rule, under the proposed stopping criterion, maintains the same asymptotic properties as
those obtained in its non-sequential counterpart. In our numerical study, for illustration
purposes, we adopt the method of Bandyopadhyay et al. (2007) and use a utility function
to balance the ethical consideration and the efficiency of the estimate for treatment allo-
cation. We, then, modify the utility function to vary the tuning parameters sequentially
depending on the precision of the estimate at every allocation stage such that subjects
are allocated to a “more adequate” treatment.
The rest of this paper is organized as follows: A sequential estimation procedure
for treatment effect is proposed in Section 2. Simulation results are applied to logistic
models using a modified allocation rule (Bandyopadhyay, Biswas, and Bhattacharya 2007)
in Section 3. We, then, conclude with discussion in Section 4. Proofs of theorems are
given in the Appendix.
2. Sequential Estimation of Treatment Effect
Let Nm,k be the number of subjects assigned to treatment k during the first m assignments
and Nm = (Nm,1, . . . , Nm,K). Suppose that {Ym,k,m = 1, 2, . . . , k = 1, . . . , K} denotes
responses of the m-th subject to the k-th treatment and Ym = (Ym,1, . . . , Ym,K). Let ξm
be the covariates of the m-th subject. Suppose that X1,X2, . . . is the sequence of random
treatment assignments, and Xm = (Xm,1, . . . , Xm,K), Xm,k ∈ {0, 1}, denotes assignment
of treatment k to the m-th subject. Then Xm,k = 1 for some k and
∑K
k=1 Xm,k = 1. That
is, each subject is allocated to one treatment only. Hence, it follows that the response of
subject m to the treatment k, Ym,k, is observed only if Xm,k = 1. (Note that this implies
that Nm =
∑m
i=1Xi.)
Define Xm = σ(X1, . . . ,Xm), Ym = σ(Y1, . . . ,Ym), and Zm = σ(ξ1, . . . , ξm), ξi ∈ Rp,
be the corresponding σ-fields. Let Fm = σ(Xm,Ym,Zm), then a general CARA design is
defined as
ψm = E[Xm|Fm−1, ξm] = E[Xm|Xm−1,Ym−1,Zm.]
5
Suppose that for each m ≥ 1, the responses and covariate vector satisfy
E[Ym,k|ξ] = µk(θk, ξ), (1)
where µk(·, ·) are known functions, Vk denotes the covariance matrix based on Equation
(1) and θk ∈ Rp for k = 1, . . . , K. The asymptotic properties of the estimate of θ =
(θ1, . . . , θK) and allocation function under such a general CARA design has been discussed
in Zhang et al. (2007). The estimation of θ is the primary goal in a clinical trial. Thus,
it will be beneficial if treatment effects can be estimated with a certain accuracy using
a minimum required sample size whilst simultaneously still retaining the good allocation
properties. Since, in a CARA design, the design at the current stage depends on the past
history, sequential analysis is the statistical tool of choie. Here a sequential estimation
procedure is proposed for constructing a confidence set for θ with a prescribed accuracy,
and we show that the asymptotic properties of allocation function remain the same as
their non-sequential counterparts under such a sequential sampling strategy.
Suppose no prior information about the effects of treatments is available. In order to es-
timate the treatment effects, at the beginning, we need to assign m0(> 0) subjects to each
treatment using restricted randomization. Hence, when we allocate the m-th subject (m >
Km0), there are already m−1 observations, {(X1,Y1, ξ1), . . . , (Xm−1,Ym−1, ξm−1)}, col-
lected. Thus, we assign the m-th subject to the treatment k with probability
ψk = P (Xm,k = 1|Fm−1, ξm) = pik(θˆm−1, ξm),
where θˆm−1 is the maximum quasi-likelihood estimate of θ based on the previous m − 1
observations and pik(·, ·) is the true allocation probability for treatment k and the given
covariate. Assume further that µk(θk, ξm) = µk(ξ
′
mθk) for each m ≥ 1. Hence, it follows
from Equation (1) and V , that the method of generalized linear models (quasi-likelihood)
can be applied (McCullagh and Nelder 1989). Assume that θk ∈ Θk ⊆ Rp is bounded for
k = 1, . . . , K, and let the parameter space Θ =
∏K
k=1 Θk.
Under the above assumptions (see also Condition A of Zhang et al. (2007), Theorem
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2.1), it is proved that as min(Nm,k, k = 1, . . . , K) goes to infinity,
√
n(θˆ − θ)→LN(0,V),
where V = diag{V1, . . . , VK}. Based on the asymptotic normality of θˆ, the sequential
method is employed for estimating the confidence set of θ = (θ1, . . . , θK). Define
R = {θ ∈ Θ : n(θˆ − θ)′V−1(θˆ − θ) ≤ C2α},
where C2α is the constant such that P (χ
2(p ·K) ≥ C2α) ≤ α. The asymptotic normality of
θˆ implies that P (θ ∈ R) ≈ 1− α as the sample size becomes large.
Although large sample results guarantee the performance of estimates and some asymp-
totic properties of CARA designs, we want to know just how large a sample size is needed
to guarantee a satisfactory performance in a practical sense. Moreover, no matter how
high the coverage probability is, the confidence set becomes less useful if the size of the
confidence set becomes too large. Now, suppose we further require that the maximum
axis of R is no larger than 2δ for some δ > 0, then the minimum sample size to achieve
this goal is
nΛmin(V
−1) ≥ C
2
α
δ2
.
Equivalently, the above inequality can be re-written as
n ≥ C
2
αΛmax(V)
δ2
, (2)
where notations Λmax(A) and Λmin(A) denote the maximum and minimum eigenvalues of
matrix A, respectively. Let Rδ denote the corresponding confidence ellipsoid for given δ.
So, once δ > 0 is specified, the maximum axis of confidence ellipsoid Rδ is no greater
than 2δ. The constant δ here is used as a measure of precision of the confidence ellipsoid
Rδ. Please refer to Siegmund (1985), Albert (1966) and Ghosh and Sen (1991) for other
measures of confidence sets.
If V is known, then the optimal sample size required to construct a confidence ellipsoid
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Rδ with the required maximum axis no greater than 2δ is
nopt = first n such that n ≥ C
2
αΛmax(V)
δ2
.
Since the variance matrix V is usually unknown, the above optimal sample size is not
available. Replacing the unknown V in Equation (2) with its consistent estimate θˆ (to
be defined later), a stopping rule to construct such a fixed size confidence ellipsoid is
suggested:
τδ = first n such that n ≥ C
2
αΛmax(Vˆ)
δ2
= inf{n ≥ n0 : n ≥ C
2
αΛmax(Vˆ)
δ2
}, (3)
where n0 ≥ Km0 is the minimum initial sample size and m0 is the initial sample size for
each treatment. Similarly, we then define
Rˆδ = {θ ∈ Θ : n(θˆ − θ)′Vˆ−1(θˆ − θ) ≤ C2α}.
It follows from the strong consistency of θˆ, if Vˆ is also a strongly consistent estimate
of V, then limn→∞ P (θ ∈ Rˆδ) = 1 − α. That is, Rˆδ is a confidence ellipsoid of θ with
coverage probability 1− α, asymptotically.
It follows from the definition of τδ that, when the sequential sampling stops, the
confidence ellipsoid will have its maximum axis no greater than 2δ. However, it is also
known that there is no guarantee that θˆ will have the same asymptotic distribution if
we replace the fixed sample size with a random sample size τδ. Although the sequential
estimation procedure provides a way to control the size of the confidence set by utilizing a
stopping rule, it is interesting to know whether the asymptotic properties in Zhang et al.
(2007) are still adhered to under such a randomly stopped criterion.
Suppose that allocation function pi(·, ·) = (pi1(·, ·), . . . , piK(·, ·)) and satisfies the fol-
lowing conditions:
(C1)
∑K
k=1 pik = 1 and 0 < νk = Eξ[pik(θ, ξ)] < 1, k = 1, . . . , K.
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(C2) For fixed ξ, pik(θ, ξ) > 0 is a continuous function of θ and is differentiable with
respect to θ such that νk(θ˜) = νk(θ) + (θ˜ − θ)(∂νk/∂θ˜)′ + o(‖θ˜ − θ‖1+ζ) for some
ζ > 0.
The condition pik > 0 for each k = 1, . . . , K on the allocation function guarantees that sub-
jects will be allocated to individual treatments, eventually. Thus, this condition also af-
firms that with probability one the design matrix is non-singular, and the Λmin(V
−1) > 0,
asymptotically. Under these conditions, in Theorem 1, we show that the sequential pro-
cedure with the stopping rule defined in (3) can guarantee that the size of the maximum
axis of confidence ellipsoid is no greater than the pre-specified length, while maintain-
ing the required coverage probability. In addition to classical asymptotic properties of
sequential confidence set estimation, the asymptotic properties of the allocation function
under sequential sampling that is based on the CARA design are also proved in Theorem
1.
Theorem 1 Under some regularity conditions on the link function µk and Conditions
(C1) and (C2) for the allocation function νk, for each k, if supm ‖ξm‖ < ∞, then the
proposed sequential estimation with the stopping rule defined in (3) has the following
properties:
(i) P (τδ <∞) = 1 and limδ→0 τδ/nopt = 1 almost surely.
When the sampling stops, the estimate of θ satisfies that
(ii) θˆτδ → θ almost surely as δ → 0,
√
τδ(θˆτδ − θ) →L N(0, V ), and limδ→0 P (θ ∈
Rδ) = 1− α.
Then, in addition, the average of the stopping rule satisfies that
(iii) limδ→0E
[
τδ
nopt
]
= 1.
Moreover, for a given allocation function, it is shown that
(iv) limδ→0
Nτδ
τδ
= ν almost surely,
(v)
Nτδ,k|ξ
Nτδ |ξ
→ pik(θ, ξ) a.s. as δ → 0, k = 1, . . . , K, and
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(vi)
√
τδ(Nτδ/τδ − ν)→L N(0,Σ),
where Nτδ,k|ξ is the number of subjects assigned to treatment k with covariate ξ up to
τδth subject and Nτδ|ξ is the total number of subjects with covariate ξ up to τδth subject.
Here ν = (ν1, · · · , νK)′ and pik, k = 1, . . . , K, depend on the allocation function, and
Σ = Σ1 + 2Σ2 where Σ1 = diag{ν} − ν′ν and Σ2 =
∑K
k=1(
∂ν
∂θk
)Vk(
∂ν
∂θk
)′.
Theorem 1 (i) states that the sequential sampling will stop eventually, and (ii) and (iii)
are named asymptotic consistency and efficiency of a sequential confidence estimation
procedure by Chow and Robbins (1965). Theorem 1 (iii) means that the average ratio of
the sequential sample size to optimal sample size converges to 1. This means the proposed
sequential sampling is efficient in terms of sample size used for constructing a fixed size
confidence ellipsoid of the parameters of interest.
Theorem 1 (iv) to (vi) provides the asymptotic properties of the allocation rule under
the sequential estimation procedure. In particular, Theorem 1 (iv) states that eventually
the allocation proportion converges to the allocation expectation ν, and Theorem 1 (v)
states that for the given covariate ξ, the proportion of allocation converges to the “true”
(unknown) allocation probability with probability one as δ goes to zero. That is, if
the conditions in Theorem 1 are satisfied, then under the proposed sequential sampling
method, the allocation rule maintains the same asymptotic properties as those in its
non-sequential sampling counterpart. In our simulation study, we have demonstrated our
procedure using the allocation rule proposed in Bandyopadhyay et al. (2007). Please
refer to Zhang et al. (2007) for different allocation functions/designs under this general
framework.
Remark 1 Note that the proof of the properties of the sequential procedure is not trivial,
and cannot follow directly from the results of the estimates based on the non-random
sample size case due to the application of the stopping rule. This can be seen from a
simple example in Chow and Teicher (1988) (Chapter 4, Example 1, page 90). Since our
proof of Theorem 1 is based on the last time approach of Chang (1999), some conditions
on the parameter space Θ can be relaxed. Details are given in the Appendix.
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2.1 Subset of parameters
Sometimes, we are only interested in contrasts of parameters. For example, instead of
estimating individual treatment effects, we may want to estimate differences between
treatment effects in a clinical trial with multiple treatments. For this purpose, let H be a
p× h matrix that specifies the contrasts with 0 < Rank(H) = h ≤ p. Let γ = H ′θ, then
the asymptotic properties of θˆ imply that as n→∞
√
n(γˆn − γ)→L N(0,Vγ),
where Vγ = H
′VH. Let Vˆγ = H ′Vˆ H. Then Vˆγ is a strongly consistent estimate of Vγ.
Therefore, it follows that n(γˆ − γ)′Vˆ−1γ (γˆ − γ) is asymptotically distributed with χ2(h).
Let
Rδγ = {γ ∈ Rh : n(γˆ − γ)′V−1γ (γˆ − γ) ≤ C2α,γ} (4)
Similarly, we can also construct a confidence ellipsoid of γ with the length of its maximum
axis no greater than 2δγ. Then the optimal sample size and its corresponding stopping
time are
nγ,opt = first n such that n ≥
C2α,γΛmax(Vγ)
δ2γ
(5)
and
τδγ = inf{n ≥ n0 : n ≥
C2α,γΛmax(Vˆγ)
δ2γ
}. (6)
By simple matrix algebra, we have a parallel theorem to Theorem 1 for contrasts of
parameters.
Theorem 2 Let H be a p × h matrix with Rank(H) = h ≤ p, and γ = H ′θ. Then
under conditions similar to Theorem 1, γˆ is a strongly consistent estimate of γ and
asymptotically normally distributed with covariance matrix Vγ = H
′VH. Moreover, the
sequential procedure with the stopping rule defined in (6) has the following asymptotical
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properties:
(i) P (τδγ <∞) = 1 and limδγ→0 τδγ/nγ,opt = 1 almost surely.
(ii) γˆτδγ → γ almost surely as δγ → 0,
√
τδγ (γˆτδγ−γ)→L N(0,Vγ), and limδγ→0 P (γ ∈
Rδγ ) = 1− α.
(iii) limδγ→0E
[
τδγ
nγ,opt
]
= 1,
where Rδγ and nγ,opt are defined in (4) and (5), respectively.
The main difference between the new stopping rule defined in Equation(6) and the
previous one is the variance of γˆ, and this difference in τδγ does not affect the allocation
rule. Therefore, the asymptotic properties of the allocation rule in Theorem 2 follow from
the same arguments as in the proof of Theorem 1. In fact, the asymptotic properties of
the allocation rule remain the same under this stopping rule, and are not re-stated here.
That is, this sequential estimation procedure allows us to compare treatment effects using
a contrast estimation method under a CARA design without disturbing the asymptotic
properties of the allocation function, which is a useful feature in practice.
Remark 2 Note that the asymptotic properties of the allocation function in Theorem 2
will remain the same as those in Theorem 1 when δγ becomes small. However, intuitively,
the sequential sample sizes should converge at different rates, depending on the contrasts.
This property is usually reflected in the second order term of the stopping time and is not
shown in Theorem 2.
3. Numerical Study
The purpose of the numerical study is to look at the performance of the estimate of the
treatment effect and the allocation of subjects. In order to apply the sequential confidence
estimation procedure proposed in Section 2 for K treatments, and treatment allocation
procedures in Section 3.1, for illustration purposes, we consider a binary response case in
this study using the logistic model.
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3.1 Treatment Allocation Rule
In order to skew the treatment allocation proportion so that the better treatment is
allocated more often, Bandyopadhyay et al. (2007) suggests using an utility function
below. For K treatments, their utility function is defined as
U(p) = log |Iˆn+1| − η
{
K∑
k=1
pk log
(
pk
pik(θˆ, ξ)
)}
, (7)
where pik(θˆ, ξ) is the estimate of pik(θ, ξ) denoting the estimate of the allocation prob-
ability for treatment k up to current stage n. For a given ξ and the current estimate
of θ, the optimal allocation rule is to find the vector of probabilities p = (p1, . . . , pK)
that maximize the utility function above. That is, the design at the (n+ 1)th stage is to
allocate the (n+ 1)th subject to the treatment that maximizes the utility function.
In the utility function, the first term is in log n scale, which is a log determinant of
the information matrix. If η = 0, then the new subject is selected to maximize the Fisher
information matrix, which is referred to as the piecewise D-optimal design as mentioned
in Bandyopadhyay et al. (2007). On the other hand, if η goes to ∞, then the optimal
value of p is to maximize the relative entropy function, the second term of (7), which was
also raised in Bandyopadhyay and Biswas (2001). Hence, the parameter η can be used
to adjust the ethical and efficiency balance. Here we use a utility function to balance the
needs for estimation precision of treatment effects and the ethical consideration. It leads
to the (locally) D-optimal design.
At the beginning of a study, when estimates of treatment effects are not reliable, we
can improve the precision of the estimation of treatment effects when allocating patients
via a utility function. Since the estimate of treatment effects becomes stable as the sample
size becomes large, it is reasonable to move the weight gradually toward the ethical part at
the later stage of the study. If there is sufficient information on treatment effects, we tend
to allocate more patients to the better treatment. That is, unlike the two-stage design in
Bandyopadhyay et al. (2007), we now have more flexibility to alter the parameters of the
utility function as sampling goes on such that the needs for estimating treatment effects
and the ethical consideration can be fulfilled and balanced.
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The second term in the utility function involves pik(θˆ, ξ). Modifying the utility function
by Bandyopadhyay et al. (2007), pik(θˆ, ξ) can be defined as follows with K = 2 for
illustration purposes.
pi1(θˆ, ξ) = J
(
ξ′θˆ1 − ξ′θˆ2
Tn
)
and pi2(θˆ, ξ) = 1− pi1(θˆ, ξ),
where J(t) can be any symmetric function. pik(θˆ, ξ) can vary sequentially through Tn at
each allocation. Both Tn and η can serve as tuning parameters between efficiency and
ethics and be random depending on the estimate precision, which can be a function of
standard deviation of the treatment effect estimate based on cumulative observations
up to nth subject. Please note that Tn and η are also tuned by a new covariate ξ
of the (n + 1)th subject. Through numerical studies, Bandyopadhyay et al. (2007)
provides tables with estimates of allocation proportions for several ηs and given Tn for two
stage CARA designs. In Section 3.2, we present numerical results with some suggestions
for tuning both parameters of Tn and η, and the proposed sequential procedure is also
evaluated with its correct allocation probability.
3.2 Application to Logistic Models
Suppose Yk = 1(0) denotes a response variable with success (failure) from a subject
assigned to treatment k for k = 1, . . . , K. Let µk(θk, ξ) = E[Yk = 1|ξ], and θk = (αk, θ∗k).
Assume that
logit(µk(θk, ξ)) = αk + θ
∗
kξ, k = 1, . . . , K. (8)
Since the covariate vector can be redefined as (1, ξ)′, without loss of generality, we assume
that αk = 0, k = 1, . . . , K. Suppose there are m0 initial samples for each treatment and
assume that we are at the mth stage with m > Km0. Then the MLE θˆm,k of θk, for
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k = 1, . . . , K, is the one that maximizes
Lk =
m∏
i=1
µ
Xi,kYi,k
i,k (1− µi,k)Xi,k(1−Yi,k), (9)
where µi,k = µk(θk, ξi). It follows that the conditional Fisher information matrix, for
given ξ, is
Ik(θk|ξ) = µk(θk, ξ)(1− µk(θk, ξ))ξξ′.
Let Iˆn,k = n
−1∑n
i=1Xi,kIk(θˆn,k|ξi) be the estimate of Ik for all k. Then for a K treatments
problem, for example, the new design is chosen such that the Fisher information matrix
Iˆn+1 is maximized, if we assume η = 0, where Iˆn+1 = Iˆn + Iˆ
n+1,
Iˆn =

1
n
∑n
i=1Xi,1λˆi,1ξiξi
′ 0 0
0
. . . 0
0 0 1
n
∑n
i=1 Xi,K λˆi,Kξiξi
′
 ,
Iˆn+1 ≡

p1λˆj,1ξjξj
′ 0 0
0
. . . 0
0 0 pK λˆj,Kξjξj
′
 , (10)
and λˆi,k = µˆi,k(1− µˆi,k) for i = 1, . . . , n, j = n+ 1, and k = 1, . . . , K.
3.2.1 Parameter Setup and Simulation Results
Suppose that K = 2; that is, we assume logistic models with binary responses, two
treatments and one continuous covariate ξ. In the logistic models, we assume equal
intercepts for both treatments (α1, α2) = (0.1, 0.1) and regression coefficients (θ
∗
1, θ
∗
2) =
(−1, 1). The covariate is generated from a mixed normal distribution with means 2
&− 2 and equal variance 1 with respective probability 0.5. Since the treatment effect is
defined as a function of differences of intercepts and regression coefficients between the
two treatments, we apply the stopping rule for the contrasts of parameters, γ = H
′
θ,
given in Section 2.1. Thus, the transpose of the contrast H is defined as a matrix with
its first row (1,−1, 0, 0) and its second row (0, 0, 1,−1), and the vector of parameters θ
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is (α1, α2, θ
∗
1, θ
∗
2)
′
.
Precision δ is assumed 0.3 and initial sample size for each treatment, m0, is assumed
as 5, 10, and 15. Several combinations of tuning parameters T0 and η are assumed: 0.5, 1
and 2 for T0 and 0, 0.1 and 1 for η. Both fixed and varying tuning parameters, T0 and η,
are considered; that is, T0 and η are fixed until the study stops, or vary whenever a new
observation is added in a way that T0 is proportional and η is inversely proportional to
the standard deviation of the treatment effect for a given covariate of a new observation.
Findings from simulation studies are as follows:
As η gets larger, stopping time gets larger but its increase is reduced as initial sample
size gets larger. Varying η does not give results that are significantly different from fixed
η unless T0 varies as well. Stopping time is very unstable when initial sample size m0 is
small, such as 5, due to unstable regression coefficient estimates at the beginning stage if
T0 is 0.5 or 2. As initial sample size gets larger, stopping time gets earlier and its variation
gets smaller. The coverage probabilities of treatment differences are reasonably close to
the nominal level 0.95 and become closer to 0.95 as the initial sample size m0 gets larger.
Based on these findings, it is recommended that, in order to obtain earlier stable stopping
time with a given precision satisfied, the initial sample size should not be too small.
When η = 0, correct treatment allocation probabilities are about 0.5, since it is equiv-
alent to randomized allocation as there is no ethical consideration in the utility function.
As η gets larger, correct treatment allocation gets better with similar performance for
positive η. This confirms that η plays a role as a tuning parameter for ethical consider-
ation and a, small, nonzero η is sufficient for correct allocation. Large correct allocation
probabilities for positive η, in Table 1, illustrate that our sequential procedure under the
CARA designs successfully implements the idea of CARA designs, with more allocation
to better treatment, for the non-sequential counterpart.
For positive η, correct allocation is high and close to 0.9 when T0 = 1 or when initial
T0=0.5 with varying T0. However, it is lower when T0 = 0.5 with fixed T0 compared to
varying T0 or when T0 = 2 with varying T0 compared to fixed T0. If T0 varies depending on
treatment effect variation, T0 becomes larger than the initial T0. Thus, varying small T0
gives better allocation due to the reasonable tuning size of T0, however, varying large T0
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gives worse allocation due to a too liberal tuning of T0. This emphasizes the importance
of selecting a reasonably sized T0.
5. Discussion
In this paper, we propose a sequential estimation scheme for the CARA design in clinical
trials. In this sequential estimation procedure, allocation function and design depend not
only on previously collected information and sequential estimates of treatment effects,
but also on the covariate information of individual subjects. The proposed sequential
estimation is based on the martingale estimating equation, which differs from some clas-
sical sequential methods that rely on independent observations. The stopping rule used
here depends on the observed Fisher information, which guarantees the precision of the
estimates of treatment effects, and is novel in the CARA design based clinical trials. The
procedure discussed here is rather general and can be applied to other generalized linear
models. We demonstrate our method using some logistic regression models under a two-
treatment case. The theorems derived in this work are for general allocation rules, which
require only mild conditions on the allocation function. It will be possible to explore more
if a specific allocation rule is available.
As shown in Figure 1, it is very difficult to allocate the most suitable treatment
for subjects in the vicinity of the intersection of lines of two treatment effects. This is
especially the case, when the difference in slopes of treatments is small. Thus, instead of
a strictly concave function as we have used in our numerical study, some concave function
with a plateau may be considered. According to our experience based on the numerical
studies, the large changes adopted in T0 during the sequential procedure may lower the
correct allocation probability. Hence, from a practical viewpoint, a reasonably sized T0
should be chosen in the utility function, considering all factors of a clinical trial, such as
the distributions of covariates, the intersection point of the two treatment models and
among others. In other words, if we have some prior information on the targeted sub-
populations, then it may help to decide T0. This leads to possible future research, where
Bayesian statistical tools might play an important role.
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Appendix A
To apply sequential sampling to CARA designs, we need to extend the results of Anscombe’s
theorem to daptive design. From the proof of Anscombe’s theorem (see Woodroofe 1982,
page 11), the i.i.d. assumption is not necessary; in fact, it only requires the sequence of
partial sum to satisfy the u.c.i.p. condition. This is sufficient for applying Anscombe’s
theorem. The lemma below shows that the sequence of the partial sum of martingale
differences also satisfies the u.c.i.p. condition. The arguments below are similar to those
of Woodroofe (1982), example 1.8.
Lemma 1 Let X1, X2, . . . be a sequence of martingale differences with respect to a se-
quence of increasing σ-field Fi for i = 0, 1, . . .; that is, E[Xi|Fi−1] = 0 for all i ≥ 1.
Suppose that there is a constant M such that E[‖Xi‖2|Fi−1] < M < ∞ for all i. Then
Yn = S
∗
n =
∑n
i=1 Xi/
√
n satisfies the u.c.i.p. condition.
Proof of Lemma 1
For all k, n ≥ 1, |S∗n+k−S∗n| ≤
√
n|Sn+k−Sn|+
[
1 +
√
n
n+k
]
|S∗n|, where Sn =
∑n
i=1 Xi. If
, δ > 0 and k ≤ nδ, then the second term on the right hand side is bounded by C(δ)|S∗n|,
where C(δ) = 1− (1 + δ)−1/2 and
P
(
C(δ)|S∗n| >

2
)
≤ P
(
|S∗n| >

2C(δ)
)
→ 0 as δ → 0,
since |S∗n| is stochastically bounded. Because Xi’s are martingale differences, instead
of Komogorov’s inequality, we apply the Ha´jek-Re´ney inequality (see Chow and Teicher
1988, Theorem 8 (iii), page 247). Then it is shown that
P
(
max
k≤nδ
|Sn+k − Sn| ≥ 
√
n
2
)
≤
(
4
n2
)
nδM =
4δM
2
,
which is independent of n and goes to zero as δ → 0. Therefore, S∗n, n ≥ 1, satisfies the
u.c.i.p. condition.
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A.1 Last time for generalized linear models
We can apply the last time method for martingale differences as that in Chang (1999) in
our proof of asymptotic efficiency.
Let σ2i ≡ Var(Yi|ξi) = σ2ν(µk). Then for fixed ρ > 0 and for each k, let’s define a last
time variable
Lk,ρ = sup{n ≥ 1 : (θ − θk)′`n(θ) > 0 ∃ θ ∈ ∂Θk,ρ},
where `n,k(θ) =
∑n
i=1 g(ξ
′
iθk)ξi(Yi,k − µk(θk, ξi) and g(t) = µ˙k/ν(µk), provided that the
derivative of µk exists. Then it follows from Chang (1999),
n > Lk,ρ ⇒ θˆk exists and θˆk ∈ ∂Θk,ρ.
Moreover, he proved that under some regularity conditions of covariate ξ’s, ELk,ρ < ∞
for all k. This implies that if we define the last time Lρ = max{L1,ρ, . . . , LK,ρ}, then
n > Lρ implies that θˆ ∈ Θρ ⊂ Θ, where Θρ =
∏K
k=1 Θk,ρ.
Note that Chang (1999) defined last times for generalized linear models, and it is clear
that for each k ∈ {1, . . . , K}, Equation (1) is a special case of Chang (1999). In Zhang
et al. (2007), they assume the estimate of θ exists in a compact set when sample size n is
sufficiently large. By the last time defined above, since we can choose sufficiently small ρ
such that for sufficiently large n, θˆ will fall into a compact neighborhood of θ. (Hence, the
assumption of Zhang et al. (2007) can be relaxed. See Chang (1999) for further details).
Although the treatment allocation for each subject is affected by previous observed
responses, it is clear that the estimate of θk, k = 1, . . . , K, is still calculated separately for
a given sample under the general CARA design. Thus the estimation procedure of θk’s
for all different k’s can be treated as estimating K adaptive regression models, separately.
That is, for given observations, the estimation of θk, for each k, does not depend on
estimates of other θl, l 6= k. That is, if for k = 1, . . . , K, let
Um,k = collection of observations {Yj,k, ξj with Xj,k = 1 : j = 1, . . . ,m},
then the estimate of θk, say θˆk, is calculated based on observations in Um,k only. Thus, the
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property of θˆk is the same as the MLE of a stochastic regression model. The sequential
estimate under the adaptive design has been studied by some authors. For example, Lai
and Wei (1982) studied its properties under a linear regression setup with a general adap-
tive design assumption, while Chen et al. (1999), and Chang (2001) discussed estimation
under a generalized linear model setup. Their results are applied in the proof of Theorem
1. (In these three papers, they only assume that the design is adaptive, but no particular
design scheme is assumed. Hence, their methods are rather general and can be applied to
our case under some specific allocation rules.)
Proof of Theorem 1
It is proved in Zhang et al. (2007) that Vˆ is a strongly consistent estimate of V. This
implies that Λmax(Vˆ) and Λmin(Vˆ) are also strongly consistent estimates of Λmax(V) and
Λmin(V), respectively. Thus, if supm ‖ξm‖ < ∞, then by Chow and Robbins (1965),
Lemma 1, it is shown that P (τδ < ∞) = 1 and limd→0 τδ/nopt = 1 with probability one
and thus the proof of (i) is completed.
The highlight of the proof of (ii) is the asymptotic normality under the random sample
size. This property can usually be obtained by applying Anscombe’s Theorem, which relies
on the u.c.i.p. property (see Woodroofe 1982). However, under the adaptive design, some
modification is required. Thus, here we apply its modification, which is stated as Lemma
1.
The asymptotic normality of θˆ under the adaptive design has been established by
Zhang et al. (2007) (see also Lai and Wei 1982, Chang 1999 and Chen et al. 1999).
Following from the results of (i), to prove (ii), it suffices to prove that the sequence of nor-
malized random sums {√n(θˆn − θ), n ≥ 1} satisfies the u.c.i.p condition (see Woodroofe
1982 for its definition). From Equation (2.4) of Zhang et al. (2007), we have, with prob-
ability one, θˆn,k − θk = n−1
∑n
m=1Xm,khk(Ym,k, ξm)(1 + o(1)) + o(n
−1/2), where function
hk satisfies E[hk(Yk, ξ)|ξ] = 0.
It follows from Zhang et al. (2007) that we have
√
n(θˆn,k − θk) = n−1/2
n∑
m=1
Xm,khk(Ym,k, ξm) + o(1)n
−1/2
n∑
m=1
Xm,khk(Ym,k, ξm) + o(1)
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almost surely. It is clear that from the definition of u.c.i.p., the property of convergence
with probability one will imply the property of u.c.i.p. Moreover, it follows from Lemma
1.4 of Woodroofe (1982), if both Un and Wn are u.c.i.p., then Un +Wn is also u.c.i.p. By
applying Lemma 1, we have that {n−1/2∑nm=1Xm,khk(Ym,k, ξm) : n ≥ 1} is u.c.i.p., which
together with Lemma 1.4 of Woodroofe (1982) implies that {√n(θˆn,k−θk) : n ≥ 1} satisfies
the u.c.i.p. condition. Hence, applying Anscombe’s theorem (Theorem 1.4 of Woodroofe
(1982); see also Theorem 4.5.3 of Govindarajulu (2004)), the asymptotic normality of θˆn,k
remains for each k, and it completes the proof of (ii).
It follows from (i), that to prove (iii), it suffices to prove that {δτδ : δ ∈ (0, 1)} is
uniformly integrable. As discussed in Section A.1,
n > Lρ ⇒ θˆn ∈ Θ.
Since Θ is compact, this implies that for n > Lρ, Λmax(Vˆk) ≤ supθ∈Θ Λmax(Vk(θ)) ≤ CΛmax
for some CΛmax > 0. Let V˜k = diag{O, . . . , Vˆk, . . . , O} for k = 1, . . . , K, where O denotes
the p×p matrix of 0’s. Then Vˆ = ∑Kk=1 V˜k. Thus, Λmax(Vˆ) ≤∑Kk=1 Λmax(V˜k) ≤ KCΛmax .
Hence, for n > Lρ, the stopping time τδ is bounded. Moreover, by applying the last time
lemma for martingale differences in Chang (1999), we have E[Lρ] <∞. This implies that
{δτδ : δ ∈ (0, 1)} is uniformly integrable and the proof of (iii) is completed.
The proofs of (iv) and (v) follow directly from Theorem 2.1, Equation (2.6) and Theo-
rem 2.2, Equation (2.8) of Zhang et al. (2007) and the strong consistency of τδ, so they are
omitted here. To prove (vi), we only need to show that {n−1/2(Nn− nν) : n = 1, 2, · · · .}
is u.c.i.p. From (A.6) of Zhang et al. (2007), we have, with probability one,
Nn − nν = Mn + (1 + o(1))
n∑
i=1
K∑
k=1
Ti,k
m
(∂ν/∂θk)
′ + o(n1/2),
where Mn = (∆Mn,1, . . . ,∆Mn,K) and Tn = (∆Tn,1, . . . ,∆Tn,K) are multi-dimensional
martingale sequences with bounded martingale differences; that is, ∆Mn,k ≤ 1 and
‖∆Tn,k‖ <∞, where ∆ denotes the operand of a sequence {zn}; that is, ∆zn = zn−zn−1.
(Here only the moment condition of martingale differences is required for our purpose.
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Thus, other properties of Mn and Tn are omitted. See Zhang et al. (2007) for further
details.) Therefore, with probability one,
n−1/2(Nn − nν) = n−1/2Mn+(1 + o(1))n−1/2
n∑
i=1
[
K∑
k=1
Ti,k
m
(∂ν/∂θk)
′
]
+ o(1).
Similarly, by applying Lemma 1 again and arguments similar to Woodroofe (1982), Ex-
ample 1.8, we have {n−1/2(Nn − nν) : n = 1, 2, · · · .} is u.c.i.p. This completes the proof
of Theorem 1 (vi).
Proof of Theorem 2
By the definition of γ = H ′θ and rank(H) = h ≤ p, it easy to see that γˆ is a strongly
consistent estimate of γ and is asymptotically normally distributed with covariance matrix
Vγ. Moreover, it is clear that {
√
n(γˆn − γ) : n = 1, 2, · · · .} is u.c.i.p., since H is a non-
random matrix. Thus, the proofs of Theorem 2 (i) and (ii) follow from the same arguments
as in the proofs of Theorem 1 (i) and (ii). To prove (iii), we first note that by simple
matrix algebra, we have
Λmax(Vˆγ) = Λmax(H
′VˆH) ≤ Λmax(H ′H) · Λmax(Vˆ).
Since H is a pre-fixed non-random matrix, Λmax(H
′H)(= λH , say) is a constant. Now, let
τ˜δγ = inf{n ≥ n0 : n ≥ λH
C2α,γΛmax(Vˆγ)
δ2γ
}.
Then by definition, we have τδγ ≤ τ˜δγ almost everywhere. Moreover, again it can be
shown by the same arguments above that {d2τ˜δγ : d ∈ (0, 1)} is uniformly integrable.
This implies that {d2τδγ : d ∈ (0, 1)} is uniformly integrable and thus the proof of (iii) of
Theorem 2 is completed.
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Figure 1: Sequential CARA design with two treatment slopes and two covariate popula-
tions.
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Table 1: Mean (M) and standard deviation (SD) of stopping time (τδγ), coverage proba-
bility (CP) and correct allocation probability (CAP) of sequential 95% confidence interval
estimation with δ = 0.3. T0V and ηV indicate whether T0 and η vary or not
Variation τδγ Variation τδγ
m0 T0 η T0V ηV M SD CP CAP m0 T0 η T0V ηV M SD CP CAP
5 0.5 0.0 N N 53 9 0.95 0.48 10 1.0 0.1 Y Y 60 11 0.96 0.87
5 0.5 0.0 Y N 58 24 0.90 0.46 10 1.0 1.0 N N 60 11 0.98 0.92
5 0.5 0.1 N N 67 21 0.94 0.76 10 1.0 1.0 N Y 63 14 0.96 0.92
5 0.5 0.1 N Y 67 23 0.93 0.74 10 1.0 1.0 Y N 65 16 0.98 0.93
5 0.5 0.1 Y N 76 34 0.92 0.88 10 1.0 1.0 Y Y 63 14 1.00 0.93
5 0.5 0.1 Y Y 66 16 0.97 0.87
5 0.5 1.0 N N 83 59 0.92 0.76 10 2.0 0.0 N N 55 14 0.92 0.47
5 0.5 1.0 N Y 70 33 0.95 0.77 10 2.0 0.0 Y N 52 14 0.97 0.46
5 0.5 1.0 Y N 81 20 0.96 0.91 10 2.0 0.1 N N 59 13 0.96 0.83
5 0.5 1.0 Y Y 75 18 0.96 0.91 10 2.0 0.1 N Y 57 12 0.99 0.83
10 2.0 0.1 Y N 54 12 0.96 0.76
5 1.0 0.0 N N 53 13 0.96 0.50 10 2.0 0.1 Y Y 56 10 0.97 0.77
5 1.0 0.0 Y N 54 13 0.94 0.49 10 2.0 1.0 N N 62 18 0.95 0.87
5 1.0 0.1 N N 69 17 0.92 0.87 10 2.0 1.0 N Y 66 22 0.92 0.88
5 1.0 0.1 N Y 68 15 0.96 0.85 10 2.0 1.0 Y N 58 12 1.00 0.84
5 1.0 0.1 Y N 66 15 0.96 0.84 10 2.0 1.0 Y Y 57 14 0.96 0.83
5 1.0 0.1 Y Y 66 16 0.86 0.84
5 1.0 1.0 N N 75 19 0.96 0.91 15 0.5 0.0 N N 52 10 0.98 0.50
5 1.0 1.0 N Y 77 18 0.98 0.91 15 0.5 0.0 Y N 51 9 0.96 0.45
5 1.0 1.0 Y N 72 13 0.96 0.90 15 0.5 0.1 N N 52 9 0.98 0.72
5 1.0 1.0 Y Y 73 19 0.99 0.90 15 0.5 0.1 N Y 53 10 0.98 0.74
15 0.5 0.1 Y N 58 12 0.98 0.87
5 2.0 0.0 N N 54 11 0.90 0.48 15 0.5 0.1 Y Y 55 14 0.98 0.90
5 2.0 0.0 Y N 53 10 0.94 0.49 15 0.5 1.0 N N 54 10 1.00 0.75
5 2.0 0.1 N N 60 14 0.99 0.79 15 0.5 1.0 N Y 54 18 0.98 0.76
5 2.0 0.1 N Y 61 14 0.96 0.79 15 0.5 1.0 Y N 57 20 0.94 0.90
5 2.0 0.1 Y N 54 10 0.98 0.73 15 0.5 1.0 Y Y 56 18 0.96 0.89
5 2.0 0.1 Y Y 57 13 0.94 0.72
5 2.0 1.0 N N 73 20 0.91 0.86 15 1.0 0.0 N N 52 9 0.96 0.50
5 2.0 1.0 N Y 71 18 0.97 0.88 15 1.0 0.0 Y N 52 10 0.97 0.43
5 2.0 1.0 Y N 59 14 0.96 0.80 15 1.0 0.1 N N 56 11 0.98 0.91
5 2.0 1.0 Y Y 57 11 0.98 0.78 15 1.0 0.1 N Y 55 13 0.98 0.90
15 1.0 0.1 Y N 55 11 0.98 0.92
10 0.5 0.0 N N 52 8 0.92 0.48 15 1.0 0.1 Y Y 53 12 0.96 0.91
10 0.5 0.0 Y N 52 10 0.92 0.46 15 1.0 1.0 N N 54 11 0.96 0.91
10 0.5 0.1 N N 58 12 0.96 0.74 15 1.0 1.0 N Y 58 18 0.96 0.93
10 0.5 0.1 N Y 59 16 0.98 0.75 15 1.0 1.0 Y N 57 12 0.94 0.95
10 0.5 0.1 Y N 63 14 0.96 0.90 15 1.0 1.0 Y Y 56 10 0.98 0.95
10 0.5 0.1 Y Y 61 13 1.00 0.91
10 0.5 1.0 N N 57 13 0.99 0.78 15 2.0 0.0 N N 52 9 0.97 0.49
10 0.5 1.0 N Y 57 14 0.97 0.74 15 2.0 0.0 Y N 52 9 0.96 0.44
10 0.5 1.0 Y N 64 16 0.93 0.92 15 2.0 0.1 N N 55 15 0.96 0.88
10 0.5 1.0 Y Y 61 12 0.98 0.92 15 2.0 0.1 N Y 54 11 1.00 0.84
15 2.0 0.1 Y N 53 10 0.97 0.83
10 1.0 0.0 N N 54 11 0.92 0.46 15 2.0 0.1 Y Y 50 8 0.96 0.79
10 1.0 0.0 Y N 52 9 0.96 0.47 15 2.0 1.0 N N 59 15 0.98 0.90
10 1.0 0.1 N N 63 16 0.98 0.90 15 2.0 1.0 N Y 54 12 0.95 0.88
10 1.0 0.1 N Y 62 17 0.94 0.87 15 2.0 1.0 Y N 55 12 0.98 0.86
10 1.0 0.1 Y N 63 14 0.96 0.89 15 2.0 1.0 Y Y 53 13 0.98 0.85
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